We Help Companies Find New Sales Opportunities
Elan is to sell Elan Drug Technologies, its drug formulation business, to Alkermes of the US for £590m.
Elan is to sell its European sales and marketing business to Medeus UK, a new pharmaceutical company backed by Apax Partners, for £66m.
Elan has acquired Dura Pharmaceuticals of the US for £1.25bn, in order to strengthen its sales force and product portfolio in North America.
Elan is seeking acquisitions to build up a salesforce in Germany and France, as part of a strategy to expand its pharmaceuticals business throughout Europe.
Elan Corp of Ireland has acquired Neurex, the Californian developer of acute care drugs, for $700m.
Elan of Ireland has announced a $600m merger with Athena Neurosciences, the Californian biotechnology concern.